Date Title Description PDF
15 Mar 2022 On significant placements in financial instruments Bestinver announces details of an accelerated book building process of approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. Download
14 Mar 2022 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book building process approximately 5% of the share capital of Laboratorios Farmacéuticos Rovi, S.A. Download
23 Feb 2022 About corporate governance The Company informs about the agreements adopted by the Board of Directors  Download
23 Feb 2022 On business and financial situation The Company releases the press release related to the full year 2021 financial results Download
23 Feb 2022 On business and financial situation The Company releases the full year 2021 financial results presentation Download

Pages

Date Title Description PDF
16 Jun 2022 Other relevant information The Company has agreed to execute the capital reduction approved by the 2022 Ordinary General Meeting to amortize the shares acquired in the framework of the own shares repurchase programs   Download
14 Jun 2022 Announcement of general shareholders’ meeting ROVI releases the information related to its General Shareholders Meeting Download
11 May 2022 On business and financial situation The Company releases the press release related to the first quarter 2022 financial result Download
11 May 2022 On business and financial situation The Company releases the first quarter 2022 financial results presentation Download
11 May 2022 Announcement of general shareholders’ meeting Rovi releases the information related to its 2022 General Shareholders Meeting Download

Pages

Date Title Description PDF
26 Feb 2019 Información sobre resultados ROVI releases the presentation related to the full year 2018 results Download
26 Feb 2019 Información sobre resultados ROVI releases the press release related to the full year 2018 results Download
15 Feb 2019 Others on business performance and financial information ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets Download
09 Jan 2019 Others on business performance and financial information ROVI informs about the adquisition of Falithrom® for the German market Download
08 Jan 2019 Liquidity contracts and specialists Liquidity contract: transactions conducted in the fourth quarter of 2018 Download

Pages